ライフサイエンスコーパス: fatty acid synthase

1 ol regulatory element-binding protein 1c and fatty acid synthase.

2 s of lipogenesis, acetyl CoA carboxylase and fatty acid synthase.

3 and highly selective inhibitor of mammalian fatty acid synthase.

4 id synthesis genes acetyl CoA carboxylase or fatty acid synthase.

5 combinant form of the thioesterase domain of fatty acid synthase.

6 demonstrated with acetyl-CoA carboxylase and fatty acid synthase.

7 ruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase.

8 hydroxy-3-methylglutaryl CoA reductase), and fatty acid synthase.

9 oacyl synthase domain of the human cytosolic fatty acid synthase.

10 radation, thiamin biosynthesis and cytosolic fatty acid synthase.

11 y-terminal thioesterase domain of the animal fatty acid synthase.

12 f both hepatic stearoyl CoA desaturase-1 and fatty acid synthase.

13 nt fatty acid product derived from mammalian fatty acid synthase.

14 the expression of acetyl-CoA carboxylase and fatty acid synthase.

15 protein, acetyl coenzyme A carboxylase, and fatty acid synthase.

16 tease serine 2, FK506-binding protein 51 and fatty acid synthase.

17 compared to the homologous dimeric mammalian fatty acid synthase.

18 ibits up-regulation of ATP citrate lyase and fatty-acid synthase.

19 acids are synthesized by type I and type II fatty acid synthases.

20 ta-ketoacyl-ACP synthase activity of type II fatty acid synthases.

21 acyl thioesters generating novel short-chain fatty acid synthases.

22 ective inhibitors of bacterial and mammalian fatty acid synthases.

23 products that target bacterial and mammalian fatty acid synthases.

24 atory element-binding protein 1c target gene fatty-acid synthase (3.0-fold), early growth response-1

25 and 18-carbon fatty acids is carried out by fatty acid synthase, a 2.6 megadalton molecular-weight m

26 acid synthetic genes, including Srebp-1 and fatty acid synthase, a pathway previously shown to be in

27 r, to the acyl carrier protein domain of the fatty acid synthase, a thioesterase active toward shorte

28 Accordingly, inhibition of fatty acid synthase-a key enzyme that mediates lipogenes

29 macologic inhibition of Rho, glutaminase, or fatty acid synthase abrogated the increased lipid conten

30 ory element-binding transcription factor 1c, fatty acid synthase, acetyl coenzyme A carboxylase 2, an

31 of the key enzymes involved in lipogenesis: fatty acid synthase, acetyl-CoA carboxylase 1, and glyce

32 cells, the mRNA levels of SREBP1-c, SREBP2, fatty-acid synthase, acetyl-CoA carboxylase, ATP citrate

33 ction of apoptosis in VarK-infected MCC with fatty acid synthase-activating antibody significantly en

34 thioesterase domain and resulted in reduced fatty acid synthase activity and an increase in product

35 We traced this defect to the uncoupling of fatty acid synthase activity from stearoyl-CoA desaturas

36 romotes insulin clearance and down-regulates fatty acid synthase activity in the liver upon its phosp

37 kinases, but requires protein synthesis and fatty acid synthase activity.

38 diates a negative acute effect of insulin on fatty acid synthase activity.

39 leptin resistance and elevated hypothalamic fatty-acid synthase activity could underlie altered ener

40 Hypothalamic fatty-acid synthase activity is also elevated in the mut

41 Ablation of type II fatty-acid synthase activity resulted in reduced intrace

42 with type I polyketide synthases and related fatty-acid synthases also extends to the interdomain con

43 de-1-beta-D-ribofuranoside) enhanced and the fatty acid synthase-AMPK inhibitor C75 (3-carboxy-4-octy

44 ovel inhibitor of the thioesterase domain of fatty acid synthase, an enzyme strongly linked to tumor

45 s, which correlates with increased levels of Fatty Acid Synthase and Acetyl CoA Carboxylase mRNAs, en

46 The expression of fatty acid synthase and acetyl-CoA carboxylase involved

47 ly increased the hepatic protein contents of fatty acid synthase and acetyl-coenzyme A carboxylase (A

48 ocess by application to the Escherichia coli fatty acid synthase and apply it to probe protein-protei

49 wnregulation of stearoyl CoA desaturase-1 or fatty acid synthase and by upregulation of hepatic chole

50 Based on recent evidence that fatty acid synthase and endogenously produced fatty acid

51 l activation of lipogenic enzymes, including fatty acid synthase and glycerol-3-phosphate acyltransfe

52 ious enzymes in lipogenic pathway, including fatty acid synthase and glycerol-3-phosphate acyltransfe

53 lipogenic genes, acetyl CoA carboxylase, and fatty acid synthase and increasing the expression of bet

54 of utilization and degradation catalyzed by fatty acid synthase and malonyl-CoA decarboxylase, respe

55 ces secretion of several proteins, including fatty acid synthase and metastasis-associated laminins.

56 ecently have been implicated in induction of fatty acid synthase and other genes.

57 the catalytic domains of multidomain type I fatty acid synthase and polyketide synthase (PKS) system

58 everal proadipogenic genes, adiponectin, and fatty acid synthase and reduced the expression of inflam

59 Fatty acid synthase and steaoryl-coenzyme A desaturase,

60 enes involved in lipid metabolism, including fatty acid synthase and steroyl coenzyme-A desaturase, t

61 ective inhibitors of bacterial and mammalian fatty acid synthases and have emerged as promising drug

62 mRNA, PPARgamma2 protein, and mRNA levels of fatty-acid synthase and acetyl-CoA carboxylase.

63 Expression of fatty-acid synthase and SCD1 was decreased in FA2H-deple

64 arboxylase), elevation in expression of FAS (fatty acid synthase), and lipid accumulation in human He

65 expression, further inducing PCSK9, SREBP-1, fatty acid synthase, and apoB mRNA.

66 n of beta-catenin, p53, p21, p27, cyclin D1, fatty acid synthase, and cyclooxygenase-2.

67 ated receptor gamma, adiponectin, perilipin, fatty acid synthase, and lipoprotein lipase.

68 member 2, solute carrier family 27 member 4, fatty acid synthase, and long-chain acyl-CoA synthetase

69 n the acyltransferase (AT) domains of DynE8, fatty acid synthase, and modular polyketide synthases, w

70 De novo lipogenesis requires fatty acid synthase, and recent studies of this enzyme s

71 ydroxy-3-methylglutaryl-coenzyme A synthase, fatty acid synthase, and stearoyl-CoA desaturase.

72 y role between malonyl-CoA, the substrate of fatty acid synthase, and the neural circuitry regulating

73 or 3-hydroxy-3-methylglutaryl-CoA reductase, fatty-acid synthase, and squalene synthase in livers of

74 y lipogenic enzymes, acetyl-CoA carboxylase, fatty-acid synthase, and stearoyl-CoA desaturase-1 were

75 Individual subunits of fatty acid synthase are proteolytically degraded when th

76 regulation of lipogenic enzymes SREBP-1c and fatty acid synthase, as well as increased hepatic lipid

77 We investigated the structure of yeast fatty acid synthase at the air-water interface by electr

78 ifunctional enzymes that resemble eukaryotic fatty acid synthases but can make highly functionalized

79 ular administration of a potent inhibitor of fatty acid synthase, C75, increases the level of its sub

80 trol encoding, for example, the cyclopropane fatty acid synthase, Cfa, the glycogen synthesis protein

81 especially the potential role of specialised fatty acid synthase complexes.

82 The type II fatty acid synthase consists of a series of individual e

83 issue indicated that nuclear localization of fatty acid synthase correlates with Gleason grade, impli

84 MFN1, MFN2 or inhibiting lipid synthesis via fatty acid synthase deficiency in AEC2 cells exacerbates

85 ketide synthase that uniquely incorporates a fatty acid synthase-derived dichloropyrrolyl extender un

86 biochemical regulators of bacterial type II fatty acid synthases due to their ability to feedback-in

87 c markers (aP2, CD36, and perilipin) and low fatty-acid synthase enzymatic activity.

88 ma gondii enoyl reductase (TgENR), a type II fatty acid synthase enzyme essential in parasites but no

89 l similarity between polyketide synthase and fatty acid synthase enzymology.

90 that fatty acid oxidation was increased and fatty acid synthase expression associated with lipogenes

91 In addition, increased fatty acid synthase expression in prostate cancer correl

92 9), (11)C-acetate uptake was independent of fatty acid synthase expression using immunohistochemistr

93 Fatty acid synthase expression was also increased in the

94 Further, leptin decreased perilipin and fatty acid synthase expression, which play an important

95 eptococcus pneumoniae, the expression of the fatty acid synthase (fab) genes is controlled by a helix

96 III (KSIII) AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the asukamycin conge

97 els in E1 and E4-mice were linked to reduced fatty acid synthase (FAS) activity and hepatic expressio

98 f nicotine increased lipolysis and inhibited fatty acid synthase (FAS) activity in a time- and dose-d

99 ly by overexpression and/or hyperactivity of fatty acid synthase (FAS) and acetyl-CoA carboxylase (AC

100 sis as reflected by increased mRNA levels of fatty acid synthase (Fas) and acetyl-CoA carboxylase (Ac

101 arrier proteins (ACPs) are essential to both fatty acid synthase (FAS) and polyketide synthase (PKS)

102 Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in hum

103 Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathways that com

104 Fatty acid synthase (FAS) catalyzes the synthesis of pal

105 atty acid chain between enzymatic domains of fatty acid synthase (FAS) during biosynthesis.

106 chanisms in the fetal liver, reduces hepatic fatty acid synthase (Fas) expression and improves glucos

107 Liver X receptor (LXR) activates fatty acid synthase (FAS) gene expression through bindin

108 related with its inability to increase liver fatty acid synthase (FAS) gene expression, which was up-

109 The fatty acid synthase (FAS) gene is significantly up-regul

110 el of intrauterine growth restriction due to fatty acid synthase (FAS) haploinsufficiency (FAS deleti

111 Fatty acid synthase (FAS) has been found to be overexpre

112 Fatty acid synthase (FAS) has been found to be overexpre

113 atory element-binding protein (Srebp) 1c and fatty acid synthase (Fas) in the liver.

114 Fatty acid synthase (FAS) inhibition initiates selective

115 The central administration of the fatty acid synthase (FAS) inhibitor, C75, rapidly suppre

116 Fatty acid synthase (FAS) inhibitors, administered syste

117 Fatty acid synthase (FAS) is a central enzyme in lipogen

118 Human fatty acid synthase (FAS) is a large, multidomain protei

119 Fatty acid synthase (FAS) is necessary for growth and su

120 tent inhibitor of the thioesterase domain of fatty acid synthase (FAS) led us to develop a concise an

121 Mevalonate depletion increased fatty acid synthase (FAS) mRNA by transcriptional mechan

122 feeding-dependent regulation of SREBP-1c and fatty acid synthase (FAS) mRNA expression in the transit

123 We developed a detailed kinetic model of the fatty acid synthase (FAS) of Escherichia coli and paired

124 Evidence links the hypothalamic fatty acid synthase (FAS) pathway to the regulation of f

125 Fatty acid synthase (FAS) promotes energy storage throug

126 Unexpectedly, the lipogenic enzyme fatty acid synthase (FAS) was increased in the skeletal

127 Fatty acid synthase (FAS), a key enzyme of the fatty aci

128 tween autophagy-related protein 8 (Atg8) and fatty acid synthase (FAS), a pivotal enzymatic complex r

129 Endogenous fatty acid synthesis, mediated by fatty acid synthase (FAS), affects membrane composition.

130 We show that fatty acid synthase (FAS), an insulin-responsive enzyme

131 or of lipid metabolism by inducing SREBP-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase (A

132 ncluding choline kinase alpha (ChoK(alpha)), fatty acid synthase (FAS), and phosphorylated ATP-citrat

133 The associations of OGA with fatty acid synthase (FAS), filamin-A, heat shock cognate

134 ing protein (aP2), lipoprotein lipase (LPL), fatty acid synthase (FAS), hormone sensitive lipase (HSL

135 nistration of C75, a potent inhibitor of the fatty acid synthase (FAS), increases malonyl-CoA concent

136 Pharmacological inhibition of fatty acid synthase (FAS), rate limiting for de novo lip

137 es involved in fatty acid synthesis, such as fatty acid synthase (FAS), sterol receptor element bindi

138 ional activators of lipogenic genes, such as fatty acid synthase (FAS), sterol regulatory element-bin

139 expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involv

140 Fatty acid synthase (FAS), the cellular enzyme that synt

141 Fatty acid synthase (FAS), the enzyme responsible for th

142 nd SREBP-2 proteins as well as expression of fatty acid synthase (FAS), the key regulatory enzyme in

143 Fatty acid synthase (FAS), the sole mammalian enzyme cap

144 er cells respond to inhibition of the enzyme fatty acid synthase (FAS), we focused on NF-kappaB-media

145 This GI contains a hybrid type I fatty acid synthase (FAS)-polyketide synthase (PKS) syst

146 ing of 5-10 standalone domains homologous to fatty acid synthase (FAS).

147 t organisms and are made endogenously by the fatty acid synthase (FAS).

148 m glucose include ATP-citrate lyase (CL) and fatty acid synthase (FAS).

149 bility to inhibit the thioesterase domain of fatty acid synthase (FAS).

150 In this assay, ACC is coupled to fatty acid synthase (FAS).

151 and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS).

152 e of the 33 kDa thioesterase domain of human fatty acid synthase (FAS-TE).

153 produced via a combination of type I and II fatty acid synthases (FAS) with FAS-I products being elo

154 Among bacterial fatty acid synthases (FAS), the Escherichia coli FAS is

155 Like fatty acid synthases (FAS), these enzymes are organized

156 Mycobacteria possess two fatty acid synthases (FAS); FAS-I carries out de novo sy

157 e elongation systems, the type I and type II fatty acid synthases (FAS-I and FAS-II respectively).

158 primary lipogenic target enzymes, including fatty-acid synthase (FAS) and acetyl-CoA carboxylase 1 (

159 esis affects atherosclerosis, we inactivated fatty-acid synthase (FAS) in macrophages of apoE-deficie

160 Fatty-acid synthase (FAS) is up-regulated in a broad ran

161 process driven by the multifunctional enzyme fatty-acid synthase (FAS), maintains endothelial functio

162 sms underlying transcriptional activation of fatty-acid synthase (FAS), we examined the relationship

163 We show there is a widespread branch of fatty acid synthase- (FAS)-like polyketide synthase (PKS

164 by competing with the enzymes of the type II fatty acid synthase (FASII) cycle for the beta-hydroxyac

165 mal stress-responsive factors, including the fatty acid synthase FASN-1, anti-microbial peptides, and

166 n-regulating their targeted genes, including fatty acid synthase (FASN) and 3-hydroxy-3-methylglutary

167 hibited CCL2-induced increases in hepatocyte fatty acid synthase (Fasn) and adipose differentiation-r

168 Fatty acid synthase (FASN) and ATP-citrate lyase, key en

169 onist CL316,243 (CL) increased expression of fatty acid synthase (FASN) and medium chain acyl-CoA deh

170 We observed a significant increase in fatty acid synthase (FASN) expression with increasing di

171 binds and hijacks the lipid-modifying enzyme fatty acid synthase (FASN) for pro-viral activity.

172 Five tagging polymorphisms in the fatty acid synthase (FASN) gene (rs1127678, rs6502051, r

173 Conditional deletion of fatty acid synthase (Fasn) in SGC impairs axon regenerat

174 noma cell growth; this required simultaneous fatty acid synthase (FASN) inhibition when FASN expressi

175 Upregulation of fatty acid synthase (FASN) is a common event in cancer,

176 Fatty acid synthase (FASN) is a key lipogenic enzyme cat

177 Fatty acid synthase (FASN) is a lipogenic enzyme that is

178 Fatty acid synthase (FASN) is an emerging tumor-associat

179 Fatty acid synthase (FASN) is commonly overexpressed in

180 Fatty acid synthase (FASN) is physiologically regulated

181 The type I fatty acid synthase (FASN) is responsible for the de nov

182 riven hepatocarcinogenesis using conditional Fatty Acid Synthase (FASN) knockout mice.

183 and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those tumors.

184 one acetylation and amounts of rate-limiting fatty acid synthase (Fasn) mRNA.

185 FAMIN formed a complex with fatty acid synthase (FASN) on peroxisomes and promoted f

186 5LO/LTB4 inhibition reduced fatty acid synthase (FASN) promoter activity and its exp

187 Recombinant orexins increased fatty acid synthase (FASN) protein levels in chicken liv

188 Fatty acid synthase (FASN) regulates de novo lipogenesis

189 al genetic and pharmacological inhibition of fatty acid synthase (FASN) suppresses toxicity induced b

190 on of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatt

191 Blockade of fatty acid synthase (FASN), a key enzyme involved in de

192 ynthesis resulted from the downregulation of fatty acid synthase (FASN), a key regulator of fatty aci

193 ng up-regulation of lipid synthesis enzymes [fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC)

194 luding fatty acid binding protein 5 (FABP5), fatty acid synthase (FASN), and monoacylglycerol lipase

195 ic enzymes [acetyl CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and stearoyl CoA desaturase

196 nkage disequilibrium in 17q25.3, which spans fatty acid synthase (FASN), coiled-coil-domain-containin

197 ulatory element-binding protein 1 (SREBP-1), fatty acid synthase (FASN), hormone-sensitive lipase (HS

198 revealed that a key enzyme in this pathway, fatty acid synthase (FASN), is relocalized to sites of D

199 (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), its effector lipogenic gene.

200 Fatty acid synthase (FASN), the enzyme responsible for d

201 Inhibition or knockdown of fatty acid synthase (FASN), the enzyme that catalyzes th

202 c model of myocardium-specific expression of fatty acid synthase (FASN), the major palmitate-synthesi

203 he HCV genotype 2a (JFH1) virus, among which fatty acid synthase (FASN), the multifunctional enzyme c

204 Fatty acid synthase (FASN), the sole cytosolic mammalian

205 ein 1c (SREBP-1c) and its downstream target, fatty acid synthase (FASN), which are key proteins invol

206 sis gene signature and specific induction of fatty acid synthase (FASN).

207 bryonic stem cells (hESCs) expressing mutant fatty acid synthase (FASN; R1819W), a metabolic regulato

208 ynthesis, one in the cytoplasm (catalyzed by fatty acid synthase, FASN) and one in the mitochondria (

209 Fatty acid synthases (FASs) and polyketide synthases (PK

210 ichment, and identification of DH enzymes in fatty acid synthases (FASs) and polyketide synthases (PK

211 and polyketide biosynthesis, and most of the fatty acid synthases (FASs) and polyketide synthases (PK

212 de synthases (PKSs) use chemistry similar to fatty acid synthases (FASs), although building block var

213 e I polyketide synthases (PKSs), and related fatty acid synthases (FASs), represent a large group of

214 cofactor protein that is required by Type II fatty acid synthases (FASs).

215 armacological proof of concept of inhibiting fatty acid synthase for the treatment of diabetes and re

216 site serine residue, or functionality of the fatty acid synthase; further shortening of the linker li

217 cruiting the histone demethylase Lsd1 to the fatty acid synthase gene promoter.

218 an be explained by the apparent absence of a fatty acid synthase gene.

219 indicates that the lipogenic "overshoot" for fatty-acid synthase gene expression known to occur durin

220 Human fatty acid synthase (hFAS) is a homodimeric multidomain

221 The human fatty-acid synthase (HFAS) is a potential target for ant

222 que carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid ch

223 ulatory element-binding protein-1 (SREBP-1), fatty acid synthase, hydroxy-3-methylglutaryl coenzyme A

224 locks for de novo fatty acid biosynthesis by fatty acid synthase I (FAS I) and for the elongation of

225 ly, EchA6 interacts with selected enzymes of fatty acid synthase II (FAS-II) in bacterial two-hybrid

226 Inhibition or inactivation of InhA, a fatty acid synthase II (FASII) enzyme, leads to mycobact

227 Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thi

228 PKD1L2 primarily associates with endogenous fatty acid synthase in normal skeletal muscle, and these

229 te carboxykinase, glucose-6-phosphatase, and fatty acid synthase in ob/ob mice.

230 xylase content and higher gene expression of fatty acid synthase in the liver indicated reduced fatty

231 t binding protein-1, acetyl-CoA carboxylase, fatty acid synthase) in the group with high VAT/(VAT+SAT

232 ciated enzymes, acetyl-CoA carboxylase-1 and fatty acid synthase, in the liver and hypothalamus.

233 and 18 carbon fatty acids is carried out by fatty acid synthase: in yeast Saccharomyces cerevisiae,

234 rostate cancer cells to proliferate, despite fatty acid synthase inhibition.

235 efect is recapitulated by treatment with the fatty acid synthase inhibitor cerulenin and is rescued b

236 ulnificus disease, was hypersensitive to the fatty acid synthase inhibitor cerulenin, showed aberrant

237 intake caused by i.c.v.-administered C75, a fatty acid synthase inhibitor that increases hypothalami

238 Correlating with this, administration of a fatty acid synthase inhibitor, cerulenin, also alleviate

239 h a surrogate of TVB-2640, a pharmacological fatty acid synthase inhibitor, has been shown to reduce

240 data support the therapeutic potential of a fatty acid synthase inhibitor, TVB-2640 in particular, i

241 In contrast, the fatty-acid synthase inhibitor cerulenin nearly completel

242 the glycolytic inhibitor, 2-deoxyglucose, or fatty acid synthase inhibitors to perturb the metabolic

243 es with KasA, a key component of the type II Fatty Acid Synthase involved in mycolic acid synthesis.

244 Because fatty acid synthase is expressed at low levels in normal

245 Fatty acid synthase is normally found in the cytosol; ho

246 As the females then enter diapause, fatty acid synthase is only sporadically expressed, and

247 the acyl chain, the overall integrity of the fatty acid synthase is quite tolerant to moderate change

248 Fatty acid synthase is up-regulated in a variety of canc

249 y acid biosynthesis by a type II dissociated fatty acid synthases is catalyzed by 3-ketoacyl-acyl car

250 yzed by both polyketide synthases (PKSs) and fatty acid synthases is most often carried out by a thio

251 ted with the accumulation of lipid reserves (fatty acid synthase) is highly up-regulated.

252 lecular features including cyclooxygenase 2, fatty acid synthase, KRAS, BRAF, PIK3CA, p53, p21, beta-

253 and the stimulation of ATP citrate lyase and fatty-acid synthase leading to de novo lipogeneis.

254 reased hyperinsulinemia-induced hypothalamic fatty acid synthase levels and activity.

255 Likewise, treatment with the fatty acid synthase/lipolysis inhibitor orlistat also se

256 We identify a fatty acid synthase mFAS (CG3524) responsible for mbCHC

257 yl-CoA activation module; and the downstream fatty acid synthase module.

258 the upstream acetyl coenzyme A formation and fatty acid synthase modules enabled further production i

259 Fatty acid synthase mRNA levels were not altered but ace

260 nic enzymes, including a >2-fold increase in fatty acid synthase mRNA, protein, and activity, there w

261 cyl carrier protein (mtACP) of mitochondrial fatty acid synthase (mtFAS).

262 n of the E1-SUMO intermediate; inhibition of fatty acid synthase; non-specific SIRT inhibition; and a

263 Up-regulation of fatty acid synthase not only increases production of fat

264 ion of genes coding for a putative cytosolic fatty acid synthase of type 1 (FAS1) and polyketide synt

265 ) and the down-regulation of the chloroplast fatty acid synthase of type 2 (FAS2).

266 Deletion of fatty acid synthase or acetyl-CoA carboxylase (ACC) 1 in

267 mponents of a putative type II mitochondrial fatty acid synthase pathway have been identified in huma

268 tein synthase (KAS) enzymes in the bacterial fatty acid synthase pathway.

269 ylcholine, which is blocked by inhibitors of fatty-acid synthase, PI 3-kinase, mTORC, or an antibody

270 t are widely used as inhibitors of mammalian fatty acid synthase, platensimycin specifically inhibits

271 rol regulatory element-binding protein 1 and fatty acid synthase protein levels in epididymal WAT of

272 Analysis of the fatty acid synthase protein sequence indicated the prese

273 sruption of the apicoplast-localized type II fatty-acid synthase resulted in greatly reduced synthesi

274 ta-oxidation, augmentation of translation of fatty acid synthase resulting in de novo lipogenesis, an

275 en the entire linker region was deleted, the fatty acid synthase retained 28% activity.

276 The acyl carrier protein (ACP) from fatty acid synthases sequesters elongating products with

277 Engineering a hybrid fatty acid synthase shifted the free fatty acids to a me

278 ession of genes involved in lipid synthesis (fatty acid synthase, squalene epoxidase, hydroxy-methylg

279 hesis genes, namely, acetyl-CoA carboxylase, fatty acid synthase, SREBP1c, chREBP, glucokinase, and p

280 g to several crucial lipid metabolism genes (fatty acid synthase, stearoyl-coenzyme A desaturase 1, a

281 involved in the de novo lipogenesis, such as fatty-acid synthase, stearoyl-CoA desaturase (SCD)-1, an

282 rted lower resolution, 4.5-Angstrom model of fatty acid synthase structure, and emphasizes the close

283 iated with a deficiency in the mitochondrial fatty acid synthase system, namely depleted lipoylation

284 he approach is broadly applicable to type II fatty acid synthase systems found in plants and bacteria

285 of the bacterial and eukaryotic multienzyme fatty acid synthase systems offer the prospect of inhibi

286 the conserved reaction chemistry of various fatty acid synthase systems, the individual isozymes tha

287 on of fas, which encodes the multifunctional fatty acid synthase that supports phospholipid and trigl

288 with the DH of the highly related animalian fatty acid synthase, the DH monomer possesses a double-h

289 ses have been studied, including the soluble fatty acid synthases, those involved in polyketide synth

290 n 1c (SREBP-1c), acetyl-CoA carboxylase, and fatty-acid synthase, three key functions in the lipogeni

291 CPS is sufficiently different from the human fatty acid synthase to justify the development of novel

292 tudies presented here show that cyclopropane fatty acid synthase transcription induced by neutral ace

293 of carcinogen-treated versus untreated mice: fatty acid synthase, transketolase, pulmonary surfactant

294 The fatty acid synthase type II (FAS-II) multienzyme system

295 an inhibition of the dehydratase step of the fatty-acid synthase type II elongation cycle.

296 suppressing the expression (and activity) of fatty acid synthase via a nonclassical pathway dependent

297 EBP1 target genes acetyl-CoA carboxylase and fatty-acid synthase was suppressed, along with suppresse

298 ol regulatory element-binding protein 1c and fatty acid synthase, were detected in the livers of Adip

299 bitor of the condensing reactions of type II fatty acid synthase, were synthesized and evaluated for

300 oblast growth factor 21, interleukin-10, and fatty acid synthase, which are all regulated by nuclear